Summit starts Phase III HARMONi-10 of ivonescimab against durvalumab in Stage III NSCLC
The global, open-label study could support registration and tests the PD-1 x VEGF bispecific as consolidation after chemoradiation in unresectable disease, with progression-free survival as its primary endpoint.
Summit Therapeutics announced on 18 November 2026 that it has begun HARMONi-10, a global, open-label Phase III trial that it describes as potentially registration-enabling. The study will evaluate ivonescimab, a PD-1 x VEGF bispecific antibody, in locally advanced, unresectable Stage III non-small cell lung cancer (NSCLC).
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
Company's press release (SEC filing): Summit Therapeutics Inc. ↗
Article written by VigiEye from the official source (Summit Therapeutics Inc.). Claims are the company's own. AI-assisted; check the source before acting.